Infection in Solid Organ Transplant Recipients Clinical Trial
Official title:
Everyone Poops: An Evaluation of the Incidence and Risk Factors for Clostridioides Difficle Infection in Solid Organ Transplant Recipients
Verified date | February 2022 |
Source | Methodist Health System |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
2.1. Study Objectives - Primary Objective(s) - Identify the incidence and risk of CDI within one year after kidney, liver, and/or pancreas transplant - Secondary Objective(s) - Identify the risk factors for recurrent CDI post-transplant in patients who were diagnosed with a CDI within one year prior to Solid Organ Transplant - Evaluate the impact of CDI on graft survival following Solid Organ Transplant
Status | Completed |
Enrollment | 585 |
Est. completion date | August 7, 2020 |
Est. primary completion date | August 7, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Solid organ transplant patients who received graft(s) at MDMC from April 1, 2015 to July 31, 2018 - Age >18 years old Exclusion Criteria: - Age <18 years old - Loss to early death defined as within one week from transplantation - Patients whose primary address is in Puerto Rico |
Country | Name | City | State |
---|---|---|---|
United States | Jessica Rago | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
Methodist Health System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of C. Difficile infection (CDI) within one year post-transplant | Incidence of C. Difficile infection within one year post-transplant for CDI post-transplant. | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant - No.1 | Risk factors transplanted organ | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant - No.2 | Origin of transplanted graft including age of donor | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No.-3 | Induction agent used | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No.4 | Acid suppression | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No.5 | First time SOT recipient | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No.6 | History of CDI in the year prior to transplant | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No.7 | Co-infection with HIV/AIDS | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No.8 | Length of hospital stay | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No. 9 | Length of intensive care unit stay | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No.10 | Intra-operative administration of blood products | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No. 11 | Antibiotic use in the 90 days prior to infection | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No. 12 | Antibiotic use in the 90 days post-transplant | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No, 13 | Hospitalization in the 90 days prior to transplantation | April 1, 2014 to July 31, 2019 | |
Primary | Risk factors for CDI post-transplant No, 14 | Hospitalization in the 90 days post-transplant | April 1, 2014 to July 31, 2019 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02260596 -
Respiratory Viral Infections in Pediatric Transplantation
|
N/A | |
Completed |
NCT01761435 -
Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination
|
Phase 3 | |
Completed |
NCT02382211 -
T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays
|
||
Terminated |
NCT01761201 -
"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".
|
Phase 3 | |
Recruiting |
NCT05626530 -
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
|
Phase 4 | |
Active, not recruiting |
NCT01527591 -
Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)
|
N/A | |
Recruiting |
NCT02503982 -
Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
|
Phase 4 | |
Completed |
NCT01446445 -
Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.
|
Phase 4 | |
Completed |
NCT01833416 -
Natural History of Cytomegalovirus (CMV) Infection and Disease Among Renal Transplant Recipients
|
N/A | |
Completed |
NCT01558037 -
Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients
|
N/A |